Proteomics study may complement the deficiency of myeloma molecular infractions

Tenley CArcher of Boston Children's Hospital Neurology and others conducted multi-group analysis of genomics, proteomics, and phosphorylation proteomics in 45 myelin tumor specimens as a potential therapeutic target for myeloma, the results of which were published in the September 2018 issue of Cancer Cell- From the articleRef:Archer TC,et al.
Cancer Cell.2018 Sep 10;34 (3): 396-410.e8doi: 10.1016/j.ccell.2018.08.004.
myeloma is a common malignant brain tumor in childrenThere are fewer genetic mutations in these tumors, so targeted treatment is difficult to carry outTenley CArcher of Boston Children's Hospital Neurology and others conducted multi-group analysis of genomics, proteomics, and phosphorylation proteomics in 45 myelin tumor specimens as a potential therapeutic target for myeloma, the results of which were published in the September 2018 issue of Cancer Cellpre-study shows that myelin cell tumors in addition to morphological heterogeneity, molecular level differences are also largeAccording to the characteristics of the tumor transcription group, it can be divided into four subtypes: Wnt type, SHH type, group 3 type and group 4 type The researchers combined the sequencing results of 45 myeloma samples from DNA methylation, RNA expression levels, and protein expression levels (Figure 1) Figure 1 Integrated classification of myelin cell tumors integrated analysis showed that myelin tumor samples with similar RNA expression saticotyped and post-translational modifications were very different The results of proteomics analysis show that SHH and group 3 each include two different subtypes There are 510 protein expression differences in SHH myelin-type myeloma a, and SHHa's protein high expression is associated with mRNA processing, shearing and transcription, as well as MYC signaling pathways, chromatin remodeling, and DNA repair In contrast, the main functions of SHHb's differential protein are associated with neuronal activity, neurotransmitters, and anti-macrophage surface antibodies (CD47) The difference between protein expression between G3a and G3b is mainly in the modification level after MYC translation, in the G3a subtype, MYC has several point modifications, such as 148th lysine acetylation and 71-bit serine phosphorylation, and myC-related regulatory protein B55a and the de-ubiquitinase USP28 are significantly higher than G3b in G3a further analysis of kinase-related pathways in tumor samples found that PRKDC is an important protein associated with DNA repair, high expression in G3 myelin tumor, inhibited PRKDC in the High MyC phosphorylation G3 myelin cell line, and enhanced tumor cell sensitivity to radiotherapy molecular parting based on mRNA expression and DNA methylation has been used as the diagnostic criterion for myelin cell tumors of WHO, proteomics and phosphorylation proteomics suggest that heterogeneity still exists in the classical molecular parting group Differences in protein expression, and even the difference in post-translation modification, provide a good way for further refinement of myelin cell tumor subtypes, and may open up new ways for patients to follow up clinical treatment.